Back to School: How biopharma can reboot drug development. Access exclusive analysis here

131I-TM-601: Additional Phase II data

In the ongoing, open-label, dose-escalation Phase II TM-601-002 trial in 59 patients

Read the full 125 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE